Japan’s Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

Keeping Toronto neighbourhoods safe is our collective responsibility. Improperly discarded needles and harm reduction supplies found in our communities have been identified as a concern. In an effort ...

The newspaper warned of signs “of a slowing economy” that should have the White House “on alert” and urged the president to nix his tariffs agenda ― which economists warn will send inflation soaring ...

The study met its primary endpoint, but analysts compared the results unfavorably to the data on Dupixent. Adjusted for placebo, 19.1% of people on rocatinlimab had 75% improvement in eczema area ...

Dupixent targets type 2 inflammation, a key driver of BP, and is the first investigational biologic to show sustained disease remission and reduce disease severity and itch compared to placebo. All ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

Mathematicians have solved a decades-old problem related to spinning a needle, in what has been hailed as one of the most important mathematical results in recent times. Once seen as “impossible ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...